Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
Funding Amount
Up to $200,000
Deadline
November 17, 2026
24 days left
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Nonprofits without 501(c)(3) status
- For-profit businesses
- Small businesses
- Tribal governments
- Tribal organizations
- Private colleges & universities
- Special district governments
- Nonprofits (501(c)(3))
Other requirements
- Territory or Possession.
Overview
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: PAR-25-096
- Total Funding: $200,000
- Instrument: grant
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Focus Areas & Funding Uses
Fields of Work
- Cancer
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
HEAL Initiative: Whole Joint Health Program (R61/R33 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
October 30, 2026
GREGoRi Data Coordination and Outreach Center (U01, Clinical Trials Not Allowed)
National Institutes of Health
Amount
$2,000,000 total
Deadline
October 30, 2026
GREGoRi Innovation Projects (U01 Clinical Trial Optional)
National Institutes of Health
Amount
$3 – $500K
Deadline
October 30, 2026
GREGoRi Technology Integration Center (U01, Clinical Trials Optional)
National Institutes of Health
Amount
$3,000,000 total
Deadline
October 30, 2026
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
November 2, 2026
Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
November 2, 2026
Ready to apply for Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed). Now let's win it.